Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications

Yu-Tzu Tai, Laurence P. Catley, Constantine S. Mitsiades, Renate Burger, Klaus Podar, Reshma Shringappaure, Teru Hideshima, Dharminder Chauhan, Makoto Hamasaki, Kenji Ishitsuka, Paul Richardson, Steven P. Treon, Nikhil C. Munshi, and Kenneth C. Anderson

The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachussets

ABSTRACT

CD40 is expressed on B-cell malignancies, including human multiple myeloma (MM) and a variety of carcinomas. We examined the potential therapeutic utility of SGN-40, the humanized anti-CD40 monoclonal antibody, for treating human MM using MM cell lines and patient MM cells (CD138⁺, CD40⁺). SGN-40 (0.01-100 μg/ml) induces modest cytotoxicity in MM cell lines and patient MM cells. In the presence of de novo protein synthesis inhibitor cycloheximide, SGN-40 significantly induced apoptosis in Dexamethasone (Dex)-sensitive MM.1S and Dex-resistant MM.1R cells and in patient MM cells. SGN-40-mediated cytotoxicity is associated with up-regulation of cytotoxic ligands of the tumor necrosis factor family (Fas/FasL, tumor necrosis factor-related apoptosis-inducing ligand, and tumor necrosis factor α). SGN-40 treatment also induces a down-regulation of CD40 dependent on an endocytic pathway. Consequently, pretreatment of MM cells with SGN-40 blocked sCD40L-mediated phosphatidylinositol 3'-kinase/AKT and nuclear factor κB activation. Importantly, pretreatment of MM.1S and MM.1R cells with SGN-40 inhibited proliferation triggered by interleukin 6 (IL-6) but not by insulin-like growth factor-I. In addition, SGN-40 pretreatment of MM.1S cells blocked the ability of IL-6 to protect against Dex-induced inhibition of DNA synthesis. This was associated with a 2-4-fold reduction of IL-6 receptor at protein and mRNA levels in SGN-40-treated MM.1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of SGN-40 as a potential new therapy to improve patient outcome in MM.

INTRODUCTION

CD40 is a M₆, 50,000 transmembrane protein in the tumor necrosis factor (TNF) receptor superfamily, which includes CD30 and CD95 (Fas/Apo-1). CD40:CD40 ligand (CD40L) interactions play a critical role in the regulation of humoral and cellular immune responses. Activation of CD40, using CD40L transfectants, soluble CD40L (sCD40L), or anti-CD40 monoclonal antibodies (mAbs), is critical for normal B-cell growth, differentiation, and isotype switching. We and others have demonstrated that CD40 is expressed on the majority of primary multiple myeloma (MM) cells (1–3). Specifically, triggering human MM cells via CD40 induces increased homotypic and heterotypic cell adhesion, up-regulation of various cell surface markers (4), translocation of Ku86/Ku70 to the cell surface (5, 6), and increased interleukin 6 (IL-6) secretion (4, 7). Ligation of CD40 with sCD40L or an anti-CD40 mAb also induces vascular endothelial growth factor (3) and urokinase-type plasminogen activator (8), suggesting its role in MM homing and migration. Several studies show that CD40 stimulation also suppresses MM cell growth (9–12). Although

the mechanism by which CD40 triggers growth arrest and apoptosis in MM cells is not delineated, wild-type p53 function is involved in these processes (9).

Because human MM remains incurable, novel biologically based therapies urgently are needed. In other cancers, mAbs and mAb-based reagents have shown clinical efficacy (13). For example, immunotherapy using antibody-targeting CD20 (rituximab), alone and in combination with chemotherapeutics, has been effective for management of B-cell lymphoproliferative diseases (14, 15). However, few MM patients express CD20 (16). The mAbs targeting CD40 on patient tumor cells represent an attractive therapeutic strategy for MM, and a variety of carcinomas also highly express CD40, broadening its potential therapeutic application. Many investigators have reported that anti-CD40 mAb can enhance antitumor activity and immunity. For example, murine anti-CD40 mAb blocked IL-6 secretion induced by MM cell adhesion to bone marrow stromal cells; because IL-6 is a key growth and survival factor for human MM cells, blockade of IL-6 secretion abrogates MM cell growth in the bone marrow milieu (4). In addition, anti-CD40 immunotoxin can effectively kill B-lineage acute lymphoblastic leukemia and non-Hodgkin’s lymphoma (17). In vivo treatment of severe combined immunodeficiency mice bearing human lymphomas with anti-CD40 antibodies inhibited tumor progression and enhanced survival (18, 19). Funakoshi et al. (20) demonstrated that murine anti-CD40 mAb was more effective at killing tumors in human B-cell lymphoma-xenografted severe combined immunodeficiency mice, in the absence of Fc receptor-bearing effector cells, than was anti-CD20 mAb to kill tumors. Subsequently, van Mierlo et al. (21) reported that systemic in vivo administration of agonistic anti-CD40 antibodies resulted in tumor eradication mediated via dendritic cell-induced CD8⁺ T-cell responses. Honeychurch et al. (22) most recently showed that anti-CD40 mAb in combination with irradiation results in CD8 T-cell-dependent immunity against B-cell lymphoma in mice, suggesting that combining irradiation with anti-CD40 mAb may provide a more potent therapeutic approach.

In the present study, we evaluated the direct impact of SGN-40 humanized anti-CD40 mAb on MM cell lines and patient cells (CD40⁺CD138⁺). SGN-40 was engineered from SGN-14 mouse mAb, which showed significant antitumor activity against human HS-Sultan and IM-9 cell line-xenografted severe combined immunodeficiency mice, without adverse effects on human normal B cells (23). We recently showed that SGN-40 triggered antibody-dependent cell-mediated cytotoxicity against CD40-expressing MM cell lines and patient cells, supporting its potential therapeutic use in human MM (24). Moreover, the tumoricidal effects of SGN-40 could not be solely attributed to enhancing effector functions of antibody-dependent cell-mediated cytotoxicity. To examine for direct induction of apoptosis, as is induced in malignant B lymphocytes by rituximab, we specifically examined the effects of SGN-40 on CD40⁺ and CD138⁺ MM.1S and MM.1R cell lines and on patient MM cells (25). SGN-40-induced cytotoxicity against MM cells is associated with up-regulation of cytotoxic ligands of the TNF family FasL, TNF-related apoptosis-inducing ligand (TRAIL), and TNF-α. Moreover, SGN-40

Received 11/19/03; revised 2/2/04; accepted 2/5/04.

Grant support: Multiple Myeloma Research Foundation Senior Research Award (Y.-T. Tai, C. Mitsiades), NIH Grants R01–50947 and PO1–78378, and the Doris Duke Distinguished Clinical Research Scientist Award and the Cure for Myeloma Fund (K. C. Anderson).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Kenneth C. Anderson, Department of Medical Oncology, Dana-Farber Cancer Institute, M557, 44 Binney Street, Boston, MA 02115. Phone: 617-632-2144; Fax: 617-632-2140; E-mail: kenneth.anderson@dfci.harvard.edu.
suppressed IL-6 receptor (IL-6R) expression at mRNA and protein levels, associated with inhibition of IL-6-mediated, but not insulin-like growth factor I (IGF-I)-mediated, MM cell growth and survival. These data provide the preclinical framework for the evaluation of SGN-40 as a novel therapy to improve patient outcome in MM.

MATERIALS AND METHODS

Cell Culture and Treatments. The CD40+ and CD138+ human MM-derived cell lines MM.1S and MM.1R were maintained as described previously (8). Freshly isolated tumor cells (CD40+, CD138+) from MM patients were obtained after informed consent and purified as described previously (8); 75% (Patient 1) and 85% (Patient 2) CD138+ cells expressed CD40. For signaling experiments, MM.1S cells were washed with RPMI and cultured in serum-deprived RPMI and 0.2% BSA overnight. For treatment with SGN40L (Alexis Biochemicals, San Diego, CA), SGN-40, or isotype control immunoglobulin (Seattle Genetics, Seattle, WA), MM cells were incubated with RPMI containing these agents. To determine whether SGN-40 inhibits CD40-mediated activation or other pathways, cells were preincubated with SGN-40 or isotype control immunoglobulin overnight and then treated with sCD40L or SGN-40 for an additional 7 min. To determine whether down-regulation of CD40 by SGN-40 occurs by the proteasome pathway, cells were pretreated with proteasome inhibitor PS341 at a nontoxic dose (2 nM) for 2 h before CD40 by SGN-40 occurs by the proteasome pathway, cells were pretreated with 10 mM ammonium chloride (Sigma, St. Louis, MO) for 2 h before treatment with sCD40L or SGN-40. To determine whether SGN-40 inhibits IL-6-induced downstream signaling and down-regulation of IL-6R, MM.1S cells were preincubated with SGN-40 overnight and then treated with IL-6 (50 ng/ml; Peprotech Inc., Rocky Hill, NJ).

Cytotoxicity Assay. MM cells (4×10⁴ cells/well) were incubated in 96-well culture plates (Costar, Cambridge, MA) in the presence of SGN-40 for 6 h and then cultured with or without cycloheximide (CHX, 0.2 μg/ml; Sigma) for an additional 36 h. Cells were pulsed with [3H]thymidine (0.5 μCi/well; NEN Products, Boston, MA) during the last 8 h of 48-h cultures, harvested onto glass filters, and counted using the LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD). To assay for inhibition of IL-6-induced cell proliferation by SGN-40, MM.1S and MM.1R cells were pretreated with 20 μg/ml of SGN-40 or control immunoglobulin overnight. They were then cultured with IL-6 (0, 50, or 200 ng/ml) or IGF-1 (0, 20, or 200 ng/ml) for 36 h before pulsing with [3H]thymidine. For IL-6-induced survival experiments, MM.1S cells pretreated with SGN-40 or control immunoglobulin were incubated with Dex (0–10 μM), in the presence or absence of IL-6 (50 ng/ml) or IGF-1 (100 ng/ml). All of the experiments were performed in triplicate. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium bromide (Chemicon International, Temecula, CA) assay, according to manufacturer’s instructions.

Reagents. The humanized anti-CD40 mAb SGN-40 (IgG1) and control human monoclonal IgG1 were provided by Seattle Genetics. CHX (0.2 μg/ml) and phosphatidylinositol 3’-kinase inhibitor LY 294002 (5 μM) were obtained from Sigma. SB203580 (5 μM) was obtained from Calbiochem (San Diego, CA). Mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitors PD98059 (10 μM) and U0126 (1 μM) were purchased from Cell Signaling Technology, Inc. (Beverly, MA). All of the antibodies for immunoblotting were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) except for anti-AKT and anti-pAKT antibody (Cell Signaling) and anti-α-tubulin mAb (Sigma).

Immunoblotting and Immunoprecipitation. MM.1S cells and patient MM cells were treated as described previously. Total cell lysates were subjected to 8–10% SDS-PAGE and transferred onto membranes; immunoblot analysis was performed as reported previously (8). For immunoprecipitation, 1 mg of lysates was incubated with anti-IL-6R antibody (4 μg) in lysis buffer for 2 h at 4°C.

Reverse Transcription-PCR. Total RNA samples were isolated using RNeasy kit (Qiagen, Valencia, CA). The first-strand cDNA was synthesized from 2 μg of total RNA priming by oligo(dT) using Superscript reverse-transcription kit (Invitrogen, Carlsbad, CA). Primers were for FasL, 5’-ggctcagcctctgaagtc-3’ and 5’-catacctgccgtgca-3’; for TRAIL (Apo-2L), 5’-agaacctggtgcctgcc-3’ and 5’-gaccaacgccacactttc-3’; for TNF-α, 5’-cttgcgccctgcccttgtggg-3’ and 5’-tctcagagaacgcccag-3’; and for CD40L, 5’-cacccctgcagagatcaccctgcc-3’ and 5’-tactgaacctgccacactttc-3’.

IL-6R DNA was amplified by reverse transcription-PCR using a primer pair (5’-cagctctgagaggtc-3’ and 5’-acacccctgccgtgca-3’) flanking the transmembrane coding region of IL-6R. The primer pair for gp130 is 5’-atactggagctctggtgc-3’ and 5’-acaagccctggagccact-3’. Real-time reverse transcription-PCR was performed on a TaqMan ABI 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) using heat-activated TaqDNA polymerase (AmpliTag Gold, Applied Biosystems). Primers for β-actin are 5’-actggagccacgaaa-3’ and 5’-acacccctgccgtgca-3’.

RESULTS

Cytotoxic Effect of SGN-40 against CD40-Expressing MM Cells. Dex-sensitive MM.1S and Dex-resistant MM.1R cells and two patient MM cells were treated with increasing concentrations (0–100 μg/ml) of SGN-40 for 48 h. DNA synthesis was measured by [3H]thymidine uptake. As shown in Fig. 1A, SGN-40 did not stimulate proliferation of MM.1S and MM.1R cells and CD40-expressing tumor cells from two MM patients (P > 0.1). To further define the cytotoxic effect of SGN-40 against MM cells, MM.1S and MM.1R cells were
treated for 6 h with SGN-40 (10 μg/ml) and then cocultured with the de novo protein synthesis inhibitor CHX (0.2 μg/ml) for an additional 48 h. Cell viability was assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. SGN-40 and CHX triggered 50–60% cell killing in both cell lines (Fig. 1B, left). Treatment with isotype control immunoglobulin alone or with CHX also did not induce cytotoxicity (Fig. 1B, right). SGN-40 triggered 20–30% cell cytotoxicity in two patient MM cells. In the presence of CHX at a nontoxic dose (0.2 μg/ml), SGN-40-induced cell cytotoxicity was enhanced significantly (Fig. 1C). These results suggested that endogenous production of cytotoxic cytokines might mediate SGN-40-induced cell death in CD40-expressing MM cells; therefore, we investigated whether SGN-40 treatment modulated expression of FasL and other cytotoxic members of the TNF superfamily, i.e., TNF-α and TRAIL (Apo-2L). Expression of FasL, TNF-α, and TRAIL increased after SGN-40 treatment, although the kinetics of induction of each gene varied (Fig. 1D).

SGN-40 Does Not Alter sCD40L-Induced Phosphorylation of AKT, IκBα, and ERK in MM.1S Cells. We next examined the signaling pathways induced by SGN-40 in MM.1S cells. Serum-starved MM.1S cells were treated with either SGN-40 or sCD40L (5 μg/ml for 0–40 min). Cell lysates were subjected to immunoblot analysis to detect activation of AKT, inhibitor of nuclear factor-κB (IκBα), and extracellular signal regulated kinase (ERK)-1/2 using phospho-specific antibodies. CD40 activation by sCD40L induces phosphorylation of AKT, IκBα, and ERK (Fig. 2A, right) as shown previously (8). In contrast, SGN-40 did not activate either AKT or IκBα phosphorylation. Phosphorylation of ERK was observed following SGN-40 stimulation, less potent than triggered by sCD40L. Little, if any, phosphorylation of AKT and IκBα was observed, even at increasing concentrations of SGN-40 (up to 1000 μg/ml; Fig. 2B).

We next studied whether combination treatments with these agents altered downstream signaling. MM.1S cells were treated with SGN-40 or sCD40L, alone or together, for 7 min. SGN-40 (5 μg/ml) did not induce phosphorylation of AKT and IκBα, whereas sCD40L alone or together with SGN-40 (5 and 10 μg/ml) induced activation of these signaling proteins (Fig. 3). Phosphorylation of ERK-1/2 was similarly induced by SGN-40, either alone or with sCD40L. MM.1S cells then were pretreated with increasing concentrations (5–1000 μg/ml) of SGN-40 for 30 min before stimulation with sCD40L (5 μg/ml). As shown in Fig. 3B, SGN-40 at either 50 or 1000 μg/ml did not significantly inhibit sCD40L-induced phosphorylation of AKT.

Pretreatment of MM Cells with SGN-40 Inhibits sCD40L-Mediated Phosphorylation of AKT/IκBα and ERK Pathways. We next measured the levels of CD40 following treatment of MM.1S cells with SGN-40 versus sCD40L. Cells were treated with sCD40L (5 μg/ml), SGN-40 (20 μg/ml), or both for the indicated time intervals. CD40 levels were measured by immunoblot analysis using anti-CD40 antibody. No changes in CD40 levels were noted at 20 min to 24 h in untreated cells (labeled Lane 1 for each time point; Fig. 4A). sCD40L treatment for 20 min to 24 h also did not alter levels of CD40 (Fig. 4A, Lane 2 compared with Lane 1). In contrast, SGN-40 triggered down-regulation of CD40 after 4 h (Fig. 4A, Lane 3) and significant inhibition of CD40 expression by 24 h.

Fig. 2. SGN-40 activates neither AKT nor nuclear factor-κB in MM.1S cells. A, serum-starved MM.1S cells were incubated with SGN-40 (5 μg/ml) or sCD40L (5 μg/ml) for the indicated time intervals. Samples were collected and evaluated by immunoblot analysis with antiphosphorylation-specific antibodies. Detection of total AKT on the same blot was used to determine equal loading of samples. B, serum-starved MM.1S cells were stimulated with SGN-40 at increasing concentrations (0–1000 μg/ml). Samples were collected and evaluated by immunoblot analysis with antiphosphorylation-specific antibodies. α-Tubulin was used as a loading control.

Fig. 3. Nuclear factor-κB (IκB) activation induced by sCD40L is not altered by SGN-40. A, serum-starved MM.1S cells were incubated with SGN-40 (5–10 μg/ml) for 7 min in the presence or absence of sCD40L (5–10 μg/ml). Isotype control immunoglobulin (5 μg/ml) was used as a control. Cell lysates were subjected to immunoblot analysis using anti-pAKT, pIκBα, and pERK1/2 antibodies, and with anti-AKT antibody as a loading control. B, serum-starved MM.1S cells were pretreated with various concentrations (5–1000 μg/ml) of SGN-40 for 30 min before stimulation with 5 μg/ml sCD40L (+) for 7 min. Cellular proteins then underwent immunoblot analysis with anti-pAKT and with anti-AKT as a loading control.

Fig. 4. SGN-40 causes down-regulation of CD40 via the endocytic pathway. A, MM.1S cells were left untreated (lanes labeled 1) or treated with 5 μg/ml of sCD40L (lanes labeled 2), 20 μg/ml of SGN-40 (lanes labeled 3), or sCD40L + SGN-40 (lanes labeled 4) for the indicated time intervals. B, cells were pretreated with 2 mM of PS341 in DMSO or DMSO alone for 2 h and then treated with sCD40L or SGN-40 for 20 min or 22 h. C, cells were pretreated with 10 mM ammonium chloride for 2 h before treatment with sCD40L or SGN-40 for indicated time intervals. Cell lysates then underwent immunoblot analysis for total levels of CD40 (Mr ~50,000) using anti-CD40 antibody.
Because many signaling molecules are regulated by ubiquitination followed by degradation by the proteasome, we next investigated whether the mechanism by which SGN-40 down-regulates CD40 is via the proteasome pathway. Cells were pretreated for 2 h with a non toxic dose (2 nm) of proteasome inhibitor PS341, followed by SCD40L or SGN-40 for 22 h. As shown in Fig. 4B, PS341 did not block down-regulation of CD40 by SGN-40 compared with cells treated with only SGN-40 or DMSO vehicle control. This suggests that down-regulation of CD40 induced by SGN-40 does not occur via proteasomal degradation. To determine whether down-regulation of CD40 was mediated by an endocytic pathway, cells were then preincubated with ammonium chloride (10 mM for 2 h) and then treated with SCD40L or SGN-40 (26). Ammonium chloride increases pH of endosomes, thereby inhibiting the endocytic pathway. Pretreatment of cells with ammonium chloride blocked SGN-40-induced down-regulation of CD40 (Fig. 4C). This result suggests that down-regulation of CD40 triggered by SGN-40 occurs via a lysosomal and endocytic pathway.

We next examined whether MM.1S cells respond to SCD40L stimulation after antibody-induced down-regulation of CD40. Cells were pretreated with either SCD40L or SGN-40 for 24 h and then either untreated or treated with additional SCD40L (5 μg/ml). Phosphorylation of AKT, IKBα, and ERK was induced by SCD40L (Fig. 5, Lanes 1–3) as shown previously. In cells pretreated with SCD40L for 24 h and then treated with additional SCD40L for 7 min, AKT, IKBα, and ERK were phosphorylated (Fig. 5, Lanes 4 and 5). In contrast, in cells pretreated with SGN-40 followed by treatment with SCD40L for 7 min, phosphorylation of AKT, IKBα, and ERK was undetected (Fig. 5, Lanes 6 and 7). Cells pretreated with SGN-40 and re-treated with additional SGN-40 did not show enhanced AKT, IKBα, and ERK phosphorylation (data not shown). Thus, 24-h pretreatment of MM.1S cells with SGN-40 blocks SCD40L-induced phosphorylation of AKT and IKBα and activation of ERK. In contrast, cells treated with SCD40L for 24 h were stimulated by subsequent treatment with additional SCD40L. These data suggest that down-regulation of CD40 by SGN-40 blocked the ability of SCD40L to trigger phosphatidylinositol 3'-kinase/AKT, nuclear factor κB, and ERK signaling.

Pretreatment of MM Cells with SGN-40 Renders Them Refractory to IL-6-, but not IGF-I-, Mediated Proliferation and Antiapoptosis. Because IL-6 and IGF-I are key MM growth and survival factors, we next asked whether SGN-40-treated MM cells respond to these cytokines in a fashion similar to control immunoglobulin-treated cells. Dex-sensitive MM.1S and Dex-resistant MM.1R cells were pretreated with SGN-40 (20 μg/ml) or control immunoglobulin for 24 h. Cells were washed, and DNA synthesis was measured after 36-h culture with IL-6 or IGF-I (0–200 ng/ml). As shown in Fig. 6A (left), IL-6-induced cell proliferation is significantly blocked in MM.1S and MM.1R cells pretreated with SGN-40 (P < 0.01) compared with the 2.5–3-fold increase in cell proliferation induced by IL-6 in control immunoglobulin-treated cells (Fig. 6A, left). In contrast, IGF-I induces cell proliferation to a similar extent in SGN-40- and control immunoglobulin-treated MM.1S and MM.1R cells. We next tested whether pretreatment with SGN-40 alters IL-6-induced protection against Dex-induced apoptosis in MM.1S cells. Cells were pretreated with SGN-40 or control immunoglobulin for 24 h, washed, and then incubated with Dex (0–10 μM) for 36 h before assay for [3H]thymidine incorporation. IL-6 (50 ng/ml) completely rescues Dex-induced cell death in control immunoglobulin-treated cells, whereas IL-6-induced protection against Dex was blocked significantly in SGN-40-pretreated cells (P < 0.023; Fig. 6B, left). In contrast and as shown in Fig. 6B (right), IGF-I-induced MM cell antiapoptosis was observed in SGN40-treated and control immunoglobulin-treated cells. These results indicate that SGN-40 pretreatment inhibits IL-6-, but not IGF-I-, mediated MM cell growth and survival.

We next examined downstream IL-6 signaling in SGN-40-treated versus control immunoglobulin-treated MM.1S cells. MM.1S cells were preincubated with SGN-40 (20 μg/ml) or isotype control immunoglobulin overnight, washed, and then stimulated with IL-6 for 0–10 min. Phosphorylation of downstream IL-6 signaling molecules (i.e., signal transducers and activators of transcription 3, ERK, and AKT) was examined by immunoblot analysis. As seen in Fig. 7, activation of these IL-6 downstream signaling molecules was reduced in SGN-40-pretreated MM.1S cells, thereby inhibiting IL-6-induced growth and survival.

SGN-40 Suppresses IL-6R (gp80) Expression at mRNA and Protein Levels. To delineate the mechanism whereby SGN-40 treatment decreases IL-6 and IL-6R signaling, we first examined whether SGN-40 treatment alters IL-6R (gp80) expression. MM.1S and a patient's MM cells (MM#1) were treated with 20 μg/ml of SGN-40 and then treated with IL-6 or IGF-I (0–200 ng/ml). As shown in Fig. 6B, left, IL-6R expression was blocked significantly in SGN-40-pretreated MM.1S cells, whereas IL-6-induced expression of IL-6R was observed in SGN-40-pretreated MM.1R cells.

Fig. 5. Pretreatment with SGN-40 inhibits phosphorylation of AKT, inhibitor of nuclear factorκB (IκBα), and extracellular signal regulated kinase (ERK) induced by SCD40L. MM.1S cells were preincubated with either 5 μg/ml of SCD40L (Lanes 4 and 5) or 20 μg/ml of SGN-40 (Lanes 6 and 7) for 24 h. After this treatment, cells were either left untreated (Lanes 4 and 6) or stimulated with 5 μg/ml of SCD40L for 7 min (Lanes 5 and 7). Lanes 1–3 show that SCD40L phosphorylates AKT, IκBα, and ERK-1/2. Immunoblot analysis also was performed with anti-AKT, anti-IκBα, and anti-ERK-1/2 antibodies. Tx, treatment.

Fig. 6. Pretreatment with SGN-40 decreases interleukin 6 (IL-6)-induced growth and survival effects. A, MM.1S and MM.1R cells were pretreated with 20 μg/ml of SGN-40 (0) or isotype control immunoglobulin (●) overnight. Cells then were treated with IL-6 (0–200 ng/ml; left) or insulin-like growth factor (IGF-I) (0–200 ng/ml; right) for 36 h and pulsed with [3H]thymidine for 8 h, and DNA synthesis was measured. B, MM.1S cells were preincubated with SGN-40 or isotype control immunoglobulin as in (A) overnight. Cells then were treated with Dex (0–10 μM) in the presence (●) or absence (○) of IL-6 (50 ng/ml) for 48 h. [3H]thymidine uptake then was measured. Cells also were treated with Dex (0, 1 μM) in the presence (●) or absence (○) of IGF-I (100 ng/ml; right).
for 3 h and 9 h, and IL-6R levels then were measured using immunoprecipitation, followed by immunoblot analysis with anti-IL-6R antibody. As shown in Fig. 8A, a 2–4-fold suppression of IL-6R was observed in MM.1S and a patient’s MM cells following 9 h of treatment with SGN-40. To confirm specific down-regulation of IL-6R expression, MM.1S and patient MM cells (MM#1) were incubated with 20 μg/ml of SGN40 or control immunoglobulin overnight followed by assessment for IL-6R by flow cytometry. Down-regulation of IL-6R expression then was evaluated by immunoblot analysis in MM.1S cells and by immunoprecipitation followed by immunoblot analysis in MM#1 cells. B, flow cytometric analysis (open histogram) of surface IL-6R expression is shown on MM.1S and patient MM cells (MM#1) treated with 20 μg/ml of either SGN40 or control immunoglobulin overnight. Shaded histogram is isotype control immunoglobulin for anti-IL-6R antibody.

DISCUSSION

We report here that humanized anti-CD40 mAb SGN-40 treatment of CD40+ and CD138+ MM cell lines and patient MM cells significantly induces growth arrest and apoptosis in the presence of the de novo protein synthesis inhibitor CHX. SGN-40-induced cytotoxicity is associated with up-regulation in cytotoxic TNF ligands (i.e., FasL, TRAIL, and TNF-α). In addition, SGN-40 suppresses expression of IL-6R protein and mRNA associated with inhibition of growth and survival of MM cells induced by IL-6 but not by IGF-I. These data support a new treatment strategy using SGN-40 to improve patient outcome in human MM.

We show that SGN-40 induces apoptosis of CD40+ and CD138+ MM cell lines and patient MM cells in the presence of CHX, in addition to its previously reported tumoricidal activity via antibody-dependent cell-mediated cytotoxicity (24). SGN-40-mediated MM cell death is associated with up-regulation of Fas/FasL because the expression of FasL was induced following SGN-40 treatment. Fas-induced apoptosis has been reported in MM.1S cells (28). We also found that SGN-40-induced cell death occurs through a caspase-8-dependent pathway (data not shown), consistent with Fas engaging a proapoptotic cascade leading to caspase activation (28–30). Furthermore, SGN-40-induced apoptosis in MM.1S and MM.1R lines is
partially inhibited by neutralizing anti-FasL antibody NOK1 (30% ± 5%; data not shown). However, the inability of neutralizing anti-FasL antibodies to abolish completely SGN-40-mediated cytotoxicity suggests additional death signals. Exposure of MM.1S cells to SGN-40 also induced transcriptional activation of other cytokotxic members of the TNF family, such as TRAIL (Apo-2L) and TNF-α, although with different kinetics. TRAIL induces MM apoptosis through the rapid activation of caspase-8, caspase-9, and caspase-3 (31). Moreover, an individual neutralizing reagent only partially protects against SGN-40-induced cell death, confirming that SGN-40-mediated MM cell apoptosis occurs via targeting more than one cytokotxigic ligand of the TNF family. Previous studies in human monocyes and normal plasma cells demonstrate the presence of high intracellular levels of FasL or TRAIL, which rapidly translocate to the cell surface in response to various stimuli (32–34). Whether SGN-40 treatment regulates the redistribution of intracellular cytokotxigic pools of these cytokotxigic ligands, in addition to their de novo transcription and translation, remains to be elucidated.

SGN-40-induced cytotoxicity in MM cells is enhanced by inhibition of protein synthesis. In particular, CHX blocks the production of protective antiapoptotic proteins (i.e., FLIP), thereby unmasking the cytotoxic potential of SGN-40. CHX-induced reduction of the short-lived antiapoptotic FLIP protein is associated with enhanced SGN-40-induced apoptosis in MM.1S cells (data not shown). Although the molecular basis for SGN-40-dependent sensitization to apoptosis in MM cells is not understood completely, this requirement of protein synthesis inhibition for efficient killing reveals a mechanism whereby MM cells, via activation of antiapoptotic cascades including AKT, Bcl-2, and Mcl-1, may escape CD40-mediated cytotoxicity. Although the ability of these pathways to block CD40-mediated cell death remains to be verified, previous studies have implicated Bcl-2, Bcl-xL, and AKT in suppression of TRAIL- and Fas-induced apoptosis in MM (35, 36).

In vitro studies have demonstrated internalization of CD40 after ligation by mAb (37, 38). Our data indicate that SGN-40 caused down-regulation of CD40 via the endosomal endocytosis, but not the proteasome-ubiquitin, pathway. It is possible that SGN-40 causes increased endocytosis without allowing for receptor recycling to the membrane, resulting in a net decrease in cell surface levels over time. An increase in receptor turnover leading to down-modulation of HER-2/c-erbB-2 or IGF-1 receptor has been reported with specific mAbs against these receptors (39, 40). In addition, rituximab therapy leads to down-regulation of CD20 expression at protein and mRNA in cells from treated patients (41). This down-modulation of targeted receptors may have important implications for scheduling and dosing, not only of anti-CD20 but also of potential novel anti-CD40 therapies.

We found down-regulation of IL-6R by SGN-40, correlating with decreased IL-6 downstream signaling and function. Because IL-6 is the major growth and survival factor for human MM, decreased IL-6R induced by SGN-40 treatment would inhibit MM cell growth and survival in the bone marrow milieu. These results are consistent with recent studies demonstrating that IFN-α (42) or IFN-γ (43, 44) significantly inhibits membrane IL-6 binding (gp80) protein and mRNA in human plasma cell lines. Since IFN-γ up-regulates CD40 expression, it may also result in additional inhibition of IL-6 expression induced by SGN-40. In contrast to its effects on IL-6 signaling, SGN-40 did not alter the proliferative and antiapoptotic effects induced by IFG-1. The mechanism by which SGN-40 treatment induces differential responses of MM cells to IL-6 and IGF-1 may, at least in part, be explained by differential changes of their cognate receptors because we could not detect any changes of IGF-1 receptor at either protein and mRNA levels induced by SGN-40 treatment (data not shown).

In summary, the humanized anti-CD40 mAb SGN-40 has direct anti-MM effects that are independent of antibody-dependent cell-mediated cytotoxicity as we reported previously (24). SGN-40 mediates apoptosis in human MM cells in the presence of CHX, and SGN-40 up-regulates cytotoxic ligands belonging to the TNF family. In addition to regulating CD40-mediated cytotoxicity, these ligands and/or their receptors also are important in apoptosis induced by a broad spectrum of stimuli, including chemotherapy and radiation. Importantly, inhibition of IL-6R expression by SGN-40 renders MM cells refractory to IL-6-induced proliferative and protective effects, thereby inhibiting MM cell growth and survival in the bone marrow microenvironment. These results provide the framework for the clinical evaluation of SGN-40 to improve patient outcome in MM.

REFERENCES
Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications


Cancer Res 2004;64:2846-2852.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/8/2846

Cited articles
This article cites 43 articles, 26 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/8/2846.full.html#ref-list-1

Citing articles
This article has been cited by 25 HighWire-hosted articles. Access the articles at:
/content/64/8/2846.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.